The potential side effects of broad spectrum HDAC inhibition has remained an obstacle in the development of cancer drugs, with numerous side effects observed [37] including nausea/vomiting, diarrhea, and fatigue in thyroid and Cutaneous T-cell lymphoma (CTCL) cancer patients. The gene discussed is HDAC9; the disease is thyroiditis.